Current management of metastatic melanoma

American Journal of Health-System Pharmacy

Volumn 65, Issue 24 SUPPL. 9, 2008, Pages

  Trinh, Van Anh ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antineoplastic agents; Dacarbazine; Decitabine; Interferon alfa; Interleukin 2; Lomeguatrib; Melanoma; Neoplasm metastasis; Radiation; Resistance; Surgery; Temozolomide

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; CARMUSTINE; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; LOMEGUATRIB; OBLIMERSEN; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HERPES ZOSTER; HUMAN; LOW DRUG DOSE; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE CYCLE TREATMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SKIN METASTASIS; TREATMENT RESPONSE;

EID: 57649170741     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080460     Document Type: Conference Paper

References (37)

1. University of Texas MD Anderson Cancer Center. Melanoma. www.mdanderson.org/diseases/melanoma/ (accessed 2008 Jul 2).
2. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995; 181:193-201.
3. Hussein MR. Extracutaneous malignant melanomas. Cancer Invest. 2008; 26:516-34.
4. American Cancer Society. Cancer Facts & Figures 2008. Atlanta, GA: American Cancer Society; 2008.
5. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol. 1996; 34:839-47.
6. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19:3635-48.
7. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998; 83:1664-78.
8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Melanoma. www.nccn.org/professionals/physician_gls/PDF/ melanoma.pdf (accessed 2008 Jul 3).
9. Conill C, Gimferrer JM, Marruecos J et al. Clinical outcome after surgical resection of lung metastases from melanoma. Clin Transl Oncol. 2007; 9:48-52.
10. Essner R, Lee JH, Wanek LA et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004; 139:961-6.
11. Meyer T, Merkel S, Goehl J et al. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000; 89:1983-91.
12. Bajetta E, Del Vecchio M, Bernard-Marty C et al. Metastatic melanoma: chemotherapy. Semin Oncol. 2002; 29:427-45.
13. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000; 5:144-51.
14. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18:158-66.
15. Brock CS, Newlands ES, Wedge SR et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58:4363-7.
16. Kurzen H, Schmitt S, Näher H et al. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs. 2003; 14:515-22.
17. Schwarzberg AB, Stover EH, Sengupta T et al. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest. 2007; 25:249-55.
18. Hofmann MA, Sterry W, Trefzer U. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit? Jpn J Clin Oncol. 2007; 37:224-9.
19. Buzaid AC, Legha S, Winn R et al. Cisplatin, vinblastine, and dacarbazine (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a phase II Cancer Community Oncology Program (CCOP) trial. Proc Am Soc Clin Oncol. 1993; 12:389.
20. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17:2745-51.
21. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006; 24:4738-45.
22. Ranson M, Hersey P, Thompson D et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol. 2007; 25:2540-5.
23. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol. 2007; 34:532-45.
24. Ranson M, Middleton MR, Bridgewater J et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2006; 12:1577-84.
25. Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag. 2007; 3:807-17.
26. D'Atri S, Tentori L, Lacal PM et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol. 1998; 54:334-41.
27. Atkins MB, Kunkel L, Sznol M et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000; 6(suppl 1):S11-4.
28. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA. 1994; 271:907-13.
29. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17:2105-16.
30. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol. 1997; 24(1 suppl 4):S39-S43.
31. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol. 2005; 6:185-93.
32. O'Day SJ, Kim CJ, Reintgen DS. Metastatic melanoma: chemotherapy to biochemotherapy. Cancer Control. 2002; 9:31-8.
33. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999; 17:968-75.
34. Ridolfi R, Chiarion-Sileni V, Guida M et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002; 20:1600-7.
35. Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005; 23:6747-55.
36. Ives NJ, Stowe RL, Lorigan P et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007; 25:5426-34.
37. Sasse AD, Sasse EC, Clark LG et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev. 2007; (1):CD005413.